work
laboratori
focus
studi
human
memori
b
cell
use
vitro
approach
dissect
trigger
requir
b
cell
unveil
distinct
role
tlr
activ
naiv
versu
memori
b
cell
use
ex
vivo
approach
analyz
dynam
memori
b
cell
asc
kinet
serum
antibodi
secondari
immun
respons
steadi
state
condit
use
quantit
data
build
model
serolog
memori
accord
model
memori
b
cell
behav
stem
cell
capabl
gener
plasma
cell
antibodi
antigendepend
well
antigenindepend
fashion
final
develop
effici
method
interrog
human
memori
b
cell
isol
human
monoclon
antibodi
method
exploit
product
neutral
antibodi
serotherapi
analyt
vaccinolog
introduct
tcelldepend
antibodi
respons
initi
b
cell
receiv
stimulatori
signal
antigentrigg
bcell
receptor
bcr
trigger
upregul
thelper
cell
upon
cognat
interact
b
cell
product
signal
event
lead
bcell
expans
gener
shortliv
antibodysecret
cell
asc
follow
germin
center
reaction
highaffin
memori
b
cell
longliv
plasma
cell
soon
antigen
stimul
serum
antibodi
reach
peak
level
subsequ
maintain
lower
constant
level
lifetim
mainten
serum
antibodi
level
immun
also
defin
serolog
memori
desir
output
vaccin
provid
immedi
protect
pathogen
toxin
cellular
base
phenomenon
howev
remain
defin
review
data
laboratori
regard
activ
requir
naiv
memori
b
cell
vivo
dynam
memori
b
cell
asc
serum
antibodi
immun
respons
steadi
state
also
discuss
model
serolog
memori
base
memori
b
cell
capac
prolifer
differenti
asc
respons
antigenindepend
environment
signal
final
illustr
exampl
memori
b
cell
interrog
exploit
make
human
monoclon
antibodi
differenti
requir
activ
memori
naiv
b
cell
human
memori
naiv
b
cell
identifi
use
combin
marker
includ
immunoglobulin
ig
isotyp
express
memori
b
cell
multidrug
transport
molecul
precis
discrimin
naiv
memori
transit
b
cell
year
ago
demonstr
human
memori
b
cell
prolifer
differenti
asc
respons
bystand
tcell
help
tcell
clone
activ
thirdparti
antigen
stimul
b
cell
noncogn
fashion
via
cytokin
product
result
earli
studi
subsequ
confirm
extend
laboratori
recent
found
memori
b
cell
constitut
express
tolllik
receptor
trigger
correspond
tlr
agonist
cpg
prolifer
differenti
asc
differ
among
memori
bcell
subset
observ
instanc
igm
memori
b
cell
abl
respond
cpg
absenc
cytokin
switch
memori
b
cell
presenc
contrast
naiv
b
cell
express
tlr
constitut
respond
directli
microbi
product
howev
rapidli
upregul
tlr
upon
bcr
stimul
data
suggest
microbi
product
play
role
memori
bcell
homeostasi
use
marker
isol
highli
pure
popul
human
naiv
b
cell
recent
address
requir
naiv
bcell
activ
found
bcr
trigger
antiig
cognat
tcell
help
provid
cell
recogn
superantigen
b
cell
suffici
induc
full
cell
expans
differenti
accumul
prolifer
b
cell
isotyp
switch
igg
iga
differenti
asc
requir
third
signal
effici
deliv
agonist
trigger
tlr
upregul
naiv
b
cell
upon
bcr
trigger
tlr
agonist
act
directli
b
cell
requir
irrespect
natur
thelper
cell
present
supernat
dendrit
cell
dc
stimul
dcspecif
tlr
agonist
also
capabl
enhanc
bcell
respons
although
much
lower
variabl
extent
requir
tlr
engag
human
naiv
bcell
activ
consist
recent
report
mous
system
howev
worth
note
import
differ
pattern
regul
tlr
express
human
mice
instanc
mous
naiv
b
cell
constitut
express
tlr
prolifer
respons
lipopolysaccharid
lp
cpg
absenc
antigen
stimuli
coupl
bcr
stimul
tlr
express
endow
human
immun
system
high
degre
specif
allow
focus
innat
signal
antigenstimul
naiv
b
cell
conclus
human
naiv
b
cell
requir
three
signal
activ
two
antigen
specif
memori
b
cell
activ
prolifer
differenti
antigenindepend
fashion
microbi
product
cytokin
bystand
tcell
help
possibl
stimuli
yet
defin
fig
fact
human
memori
b
cell
polyclon
activ
varieti
environment
stimuli
may
relat
high
spontan
vivo
turnov
cell
discuss
serum
antibodi
repres
particularli
inform
easytomeasur
paramet
evalu
immun
statu
individu
reveal
previou
antigen
exposur
estim
degre
protect
spite
wide
use
diagnost
purpos
monitor
efficaci
vaccin
littl
known
serum
antibodi
level
regul
differ
time
immun
maintain
constant
absenc
antigen
stimul
long
period
time
mous
studi
identifi
two
distinct
mechan
contribut
sustain
serum
antibodi
level
first
longev
plasma
cell
one
studi
demonstr
antigenspecif
plasma
cell
surviv
appropri
nich
bone
marrow
sever
month
without
divid
anoth
studi
show
serum
antibodi
level
reach
follow
immun
maintain
constant
one
year
declin
mice
irradi
indic
radiationresist
plasma
cell
surviv
halflif
approxim
day
latter
result
suggest
divid
cell
contribut
mainten
serum
antibodi
mechan
particularli
signific
time
observ
exce
one
year
anoth
mechan
sustain
antibodi
level
continu
antigen
stimul
persist
antigen
mice
immun
protein
antigen
show
transient
antibodi
respons
serum
antigen
express
live
viru
induc
sustain
antibodi
level
antigen
persist
follicular
dc
fdc
may
relev
phenomenon
role
cell
mainten
serum
antibodi
level
remain
address
although
mous
studi
inform
one
consid
great
differ
lifespan
degre
environment
antigen
exposur
human
experiment
mice
rais
specif
pathogenfre
environ
human
studi
shown
peak
level
serum
antibodi
reach
follow
acut
infect
immun
declin
initi
period
month
serum
antibodi
maintain
constant
level
decad
eventu
lifetim
absenc
addit
antigen
stimul
strike
exampl
fact
serum
antibodi
vaccinia
viru
well
vaccinia
virusspecif
memori
b
cell
still
detect
year
vaccin
spite
fact
viru
highli
cytopath
nonpersist
circul
popul
sever
consider
suggest
longev
plasma
cell
andor
persist
antigen
suffici
account
extraordinari
longev
human
serolog
memori
instanc
human
plasma
cell
surviv
lifetim
mass
consequ
total
serum
ig
level
increas
steadili
age
individu
phenomenon
observ
furthermor
recent
shown
upon
booster
immun
newli
form
asc
displac
old
plasma
cell
bone
marrow
find
consist
substanti
turnov
plasma
cell
bone
marrow
depend
antigen
stimul
competit
surviv
nich
resid
plasma
cell
new
plasma
cell
migrat
bone
marrow
peripheri
longliv
plasma
cell
bone
marrow
continu
turn
homeostat
mechan
must
exist
sustain
serum
antibodi
level
combin
two
quantit
assay
measur
amount
serum
igg
frequenc
iggproduc
memori
b
cell
blood
found
steadi
statecondit
ie
least
one
year
antigen
boost
strike
correl
frequenc
antigenspecif
b
cell
memori
pool
antigenspecif
igg
level
serum
correl
found
differ
antigen
individu
wide
distribut
serum
antibodi
memori
b
cell
follow
standard
vaccin
observ
suggest
steadyst
condit
memori
b
cell
plasma
cell
antibodi
part
homeostat
system
maintain
pool
size
continu
divis
differenti
absenc
antigen
review
evid
homeostat
mainten
serolog
memori
homeostat
mainten
serolog
memori
requir
entir
memori
bcell
pool
continu
divid
differenti
respons
antigen
nonspecif
stimuli
fact
consist
previous
describ
activ
properti
memori
b
cell
recent
studi
use
vivo
label
heavi
glucos
ex
vivo
express
indic
approxim
human
memori
b
cell
divid
everi
day
subset
mous
memori
b
cell
call
preplasma
cell
also
shown
prolifer
differenti
absenc
antigen
found
steadyst
condit
continu
low
rate
product
asc
detect
peripher
blood
approxim
per
million
mononuclear
cell
fig
asc
secret
antibodi
memori
specif
proport
frequenc
specif
memori
b
cell
also
found
upon
tetanu
toxoid
tt
boost
number
circul
asc
produc
antibodi
unrel
memori
specif
increas
find
consist
increas
polyclon
activ
memori
b
cell
possibl
due
increas
bystand
tcell
help
note
transient
polyclon
natur
bystand
respons
expect
lead
signific
increas
serum
antibodi
level
taken
togeth
find
delin
antigenindepend
mechan
continu
plasma
cell
gener
homeostasi
contribut
maintain
serum
antibodi
level
import
point
understand
differenti
contribut
antigendepend
antigenindepend
mechan
serolog
respons
memori
obtain
quantit
data
would
allow
us
discrimin
antigendepend
antigenindepend
compon
serolog
respons
studi
dynam
memori
b
cell
asc
kinet
serum
antibodi
level
follow
immun
fig
found
upon
boost
tt
larg
number
ttspecif
asc
ml
appear
peripher
blood
day
day
return
baselin
level
day
ttspecif
serum
igg
antibodi
increas
day
day
reach
level
high
mgml
antibodi
remain
plateau
level
approxim
one
month
declin
progress
period
six
eight
month
halflif
approxim
day
reach
eventu
plateau
stabl
rest
observ
time
case
one
year
plateau
lower
peak
level
higher
preboost
level
correl
increas
frequenc
specif
memori
b
cell
detail
analysi
experiment
data
allow
us
draw
sever
conclus
first
antigen
boost
induc
rapid
increas
serum
antibodi
sustain
month
contrast
mous
system
serum
antibodi
maintain
constant
peak
level
year
second
antigeninduc
asc
respons
rapid
increas
serum
antibodi
short
live
elimin
increas
observ
day
howev
asc
short
live
serum
antibodi
level
start
declin
day
halflif
approxim
day
halflif
human
predomin
isotyp
induc
addit
quantit
paramet
could
estim
typic
secondari
respons
tt
total
serum
concentr
mgml
halflif
day
allow
us
estim
synthet
rate
mgmlday
thu
approxim
mg
antittspecif
antibodi
produc
two
day
day
day
shortliv
asc
base
assumpt
halflif
bone
marrow
plasma
cell
ttspecif
plasma
cell
approxim
day
therefor
turnov
per
day
estim
day
boost
bone
marrow
plasma
cell
tt
specif
produc
mgmlday
antitt
antibodi
rate
product
suffici
sustain
serum
antibodi
level
plateau
phase
antibodi
produc
shortliv
asc
replac
synthes
longliv
plasma
cell
consist
subsequ
declin
phase
due
turnov
longliv
plasma
cell
taken
togeth
studi
delin
antigendepend
antigenindepend
polyclon
compon
togeth
contribut
serolog
respons
observ
immun
develop
memori
accordingli
shortterm
serolog
memori
longterm
serolog
memori
could
defin
first
mediat
antigendriven
product
shortliv
longliv
plasma
cell
wherea
second
mediat
antigenindepend
homeostat
activ
memori
b
cell
lead
sustain
product
plasma
cell
memori
specif
one
hand
upon
antigen
stimul
specif
memori
b
cell
prolifer
give
rise
larg
number
plasma
cell
antibodi
maintain
possibl
increas
pool
hand
absenc
antigen
memori
b
cell
continu
prolifer
low
rate
spill
plasma
cell
replac
turnov
thu
maintain
constant
antibodi
level
therefor
propos
memori
b
cell
function
memori
stem
cell
capabl
maintain
pool
size
continu
gener
maintain
pool
differenti
cell
limit
lifespan
success
vaccin
reli
gener
protect
antibodi
level
protect
rel
particular
pathogen
may
mediat
preform
antibodi
antibodi
rapidli
produc
asc
deriv
prolifer
memori
b
cell
combin
case
toxin
often
time
mount
secondari
prolif
respons
therefor
protect
reli
entir
preexist
neutral
antibodi
serolog
respons
describ
show
high
level
antibodi
induc
within
week
antigen
boost
maintain
month
high
number
memori
b
cell
requir
secondari
antibodi
respons
inde
found
magnitud
antibodi
respons
correl
frequenc
exist
antigenspecif
memori
b
cell
rather
invers
correl
preboost
antibodi
level
e
traggiai
unpublish
data
find
consist
neg
feedback
effect
exist
antibodi
secondari
respons
contrast
high
number
memori
b
cell
requir
sustain
serum
antibodi
period
sever
year
therefor
induc
longliv
protect
vaccin
gener
memori
b
cell
frequenc
high
enough
maintain
protect
antibodi
level
frequenc
achiev
upon
natur
infect
immun
live
vaccin
vaccinia
viru
contrast
weak
immunogen
protein
antigen
poor
induc
memori
b
cell
repetit
immun
appear
requir
increas
memori
bcell
frequenc
appropri
level
togeth
activ
vaccin
passiv
vaccin
also
call
serotherapi
act
administr
preform
specif
antibodi
one
great
contribut
immunolog
medic
treatment
monoclon
antibodi
use
offer
immedi
protect
varieti
toxin
pathogen
includ
emerg
one
sever
acut
respiratori
syndrom
sar
influenza
polyclon
human
ig
hyperimmun
sera
avail
suffici
amount
monoclon
antibodi
repres
ideal
altern
hyperimmun
sera
produc
immort
memori
b
cell
epsteinbarr
viru
ebv
fuse
b
cell
appropri
partner
cell
produc
hybridoma
method
use
low
effici
therefor
altern
strategi
develop
altern
includ
human
murin
monoclon
antibodi
protein
engin
select
antibodi
phage
display
librari
human
antibodi
fragment
immun
transgen
mice
carri
human
ig
loci
follow
product
monoclon
antibodi
use
hybridoma
technolog
although
method
led
develop
sever
therapeut
monoclon
antibodi
cytokin
surfac
molecul
impact
infecti
diseas
therapi
less
pronounc
inde
number
therapeut
antibodi
infecti
agent
still
limit
one
current
use
prevent
respiratori
syncyti
viru
rsv
infect
newborn
obviou
advantag
use
human
b
cell
produc
monoclon
antibodi
first
human
mount
power
immun
respons
includ
antibodi
long
complementaritydetermin
region
region
second
antibodi
fulli
human
select
human
bodi
minim
risk
cross
reactiv
selfantigen
third
human
immun
respons
direct
virul
pathogen
target
compon
necessari
infect
virul
usual
invis
immun
system
differ
host
instanc
mous
recent
describ
improv
method
ebv
transform
human
b
cell
base
addit
tlr
agonist
ebv
transform
clone
use
method
isol
neutral
nonneutr
monoclon
antibodi
varieti
target
includ
virus
sar
coronaviru
toxin
parasit
exampl
abl
isol
independ
monoclon
antibodi
antibodi
one
individu
recov
sar
infect
neutral
high
potenc
viru
infect
vitro
low
antibodi
concentr
use
panel
antibodi
differ
neutral
titer
found
vitro
potenc
precis
correl
vivo
efficaci
measur
reduct
viral
titer
lung
k
subbarao
lanzavecchia
unpublish
data
envis
method
may
use
isol
therapeut
antibodi
passiv
vaccin
also
analyz
antibodi
repertoir
immun
vaccin
individu
identifi
neutral
enhanc
irrelev
epitop
thu
guid
formul
candid
vaccin
analyt
vaccinolog
particularli
use
case
highli
variabl
virus
hepat
c
viru
human
immunodefici
viru
highli
complex
pathogen
plasmodium
